Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Novobiocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 1.00 |
| ▸ | MAP1LC3A | Q9H492 | 2/20 | 1.00 |
| ▸ | POLQ | O75417 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.87 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Novobiocin SCHEMBL14418054 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL12077083 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL16801983 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL12967913 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL24229298 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL15314954 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL24589148 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL24336906 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL23416512 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ | |
| Novobiocin SCHEMBL22023678 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAP1LC3BMAP1LC3APOLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12539 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | claimed |
| US-12624127-B2 | Chitosan derivatives as antimicrobials and synergistic combinations thereof | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2026-05-12 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260091127-A1 | JANUS PARTICLE-EMBEDDED MATERIALS FOR ANTIMICROBIAL APPLICATIONS | UNIV INDIANA TRUSTEES (US) | 2026-04-02 | — | — | US | claimed |
| EP-4683630-A1 | VPS4B INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | Institut Curie (FR) | 2026-01-28 | — | — | EP | claimed |
| EP-4646432-A1 | ANTI-IL-18BP ANTIBODIES | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4646433-A1 | ANTI-IL-18BP ANTIBODIES | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| WO-2025224715-A1 | METHODS FOR IMPROVING PRECISE GENOME MODIFICATION AND REDUCING UNWANTED MUTATIONS BY CRISPR-CAS EDITING | KING ABDULLAH UNIVERISTY OF SCIENCE AND TECHNOLOGY (SA) | 2025-10-30 | — | — | WO | claimed |
| US-20250263799-A1 | METHODS OF TREATING CANCER USING REPLICATION STRESS MODULATORS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2025-08-21 | — | — | US | claimed |
| US-12377052-B2 | Dual-responsive nanoparticles for enhanced antibacterial efficacy | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-08-05 | — | — | US | claimed |
| EP-0025698-B1 | CONTROLLED RELEASE FORMULATIONS | ELI LILLY AND COMPANY (US) | 1984-06-13 | — | — | EP | claimed |
| EP-0058867-A1 | Method of producing a tricalcium phosphate bone ceramic for application as a bone implant, especially to fill cavities or for setting bone fractures in place after fracture, and tricalcium phosphate ceramic shaped articles produced according to this method | mundipharma GmbH (DE) | 1982-09-01 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4304855-A | Allylic methyl-hydroxylated novobiocins | THE UPJOHN COMPANY (US) | 1981-12-08 | — | — | US | claimed |
| US-4293539-A | Controlled release formulations and method of treatment | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| US-4289757-A | TOPICAL APPLICATION OF ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1981-09-15 | — | — | US | claimed |
| US-4288543-A | SAMPLING IN LIQUID PHASE WITH ANTIGROWTH AGENTS-BIOLOGICAL | PFIZER INC. (US) | 1981-09-08 | — | — | US | claimed |
| EP-0025698-A2 | Controlled release formulations | ELI LILLY AND COMPANY (US) | 1981-03-25 | — | — | EP | claimed |
| US-4191740-A | Synthetic resin-base, antibiotic compositions containing amino acids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-03-04 | — | — | US | claimed |
| US-3932615-A | Process for the preparation of granules | MEIJI SEIKA CO., LTD. (JA) | 1976-01-13 | — | — | US | claimed |